BioMarin Pharmaceutical Inc. (BMRN)
Preborsa:
| Chiusura precedente | 84,45 |
| Aperto | 84,10 |
| Denaro | 0,00 x 900 |
| Lettera | 84,65 x 1100 |
| Min-Max giorno | 83,57 - 85,05 |
| Intervallo di 52 settimane | 71,59 - 92,17 |
| Volume | |
| Media Volume | 1.500.648 |
| Capitalizzazione | 15,541B |
| Beta (5 anni mensile) | 0,49 |
| Rapporto PE (ttm) | 2.351,39 |
| EPS (ttm) | 0,04 |
| Prossima data utili | 23 feb 2022 - 28 feb 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 116,68 |
- GlobeNewswire
BMRN FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December 22, 2021 lead plaintiff deadline. SO WHAT: If you purchased BioMarin securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen
- GlobeNewswire
BMRN & RECAF – Upcoming Lead Deadlines: Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as le
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline – BMRN
NEW YORK, Dec. 19, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities bet
